Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study

ABSTRACT: Background: An excess risk of Bell's palsy has been suggested after mRNA vaccines. We examined the association between the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy. Methods: Using the database of the largest healthcare provider in Israel, we retrieved data from different...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rana Shibli, Ofra Barnett, Zomoroda Abu-Full, Naomi Gronich, Ronza Najjar-Debbiny, Ilana Doweck, Gad Rennert, Walid Saliba
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	adverse events Bell's palsy facial paralysis BNT162b2 mRNA COVID-19 vaccine COVID-19 mRNA vaccines Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/a4d0dbc2f25d4691a7609a1d56bff071
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a4d0dbc2f25d4691a7609a1d56bff071
record_format	dspace
spelling	oai:doaj.org-article:a4d0dbc2f25d4691a7609a1d56bff0712021-12-02T05:04:19ZAssociation between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study2666-776210.1016/j.lanepe.2021.100236https://doaj.org/article/a4d0dbc2f25d4691a7609a1d56bff0712021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666776221002222https://doaj.org/toc/2666-7762ABSTRACT: Background: An excess risk of Bell's palsy has been suggested after mRNA vaccines. We examined the association between the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy. Methods: Using the database of the largest healthcare provider in Israel, we retrieved data from different periods in 2018-2021. Observed cases of Bell's palsy occurring within 21-days after the first vaccine dose and within 30-days after the second vaccine dose were compared to the expected cases, based on the experience of the population in 2019. Standardized incidence ratios (SIRs) and attributable risks (ARs) were computed. Findings: Overall, 132 cases of Bell's palsy were reported in 2,594,990 vaccinees with the first dose, and 152 cases in 2,434,674 vaccinees after the second dose. The age and sex weighted SIRs were 1.36(95% CI, 1.14-1.61) and 1.16(0.99-1.36) after the first and second vaccine dose, respectively. SIRs tended to be higher in older age groups after the first and second vaccine doses. The estimates were more pronounced in older females after the first vaccine dose; SIR=1.71(1.10-2.54) at age 45-64, and 2.51(1.65-3.68) at age ≥65 years. The highest AR was 4.46 per 100,000 vaccinees detected in females aged ≥65 years. In patients with previous history of Bell's palsy, only 4 cases of Bell's palsy were reported in 7,567 vaccinees and 10 cases in 7,045 vaccinees after the first and the second dose, respectively. The age and sex weighted SIRs were 1.15(0.36-2.76) and 2.15(1.09-3.83) after the first and second vaccine dose, respectively. Interpretation: This study suggests that the BNT162b2 mRNA COVID-19 vaccine might be associated with increased risk of Bell's palsy. The small estimated attributable risks suggest that the impact on public health is relatively minor. The benefits of vaccinations explicitly outweigh the possible link to Bell's palsy that has high recovery rate if timely treated with corticosteroids. Funding: No external funding was available for this study.Rana ShibliOfra BarnettZomoroda Abu-FullNaomi GronichRonza Najjar-DebbinyIlana DoweckGad RennertWalid SalibaElsevierarticleadverse eventsBell's palsyfacial paralysisBNT162b2 mRNA COVID-19 vaccineCOVID-19mRNA vaccinesPublic aspects of medicineRA1-1270ENThe Lancet Regional Health. Europe, Vol 11, Iss , Pp 100236- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	adverse events Bell's palsy facial paralysis BNT162b2 mRNA COVID-19 vaccine COVID-19 mRNA vaccines Public aspects of medicine RA1-1270
spellingShingle	adverse events Bell's palsy facial paralysis BNT162b2 mRNA COVID-19 vaccine COVID-19 mRNA vaccines Public aspects of medicine RA1-1270 Rana Shibli Ofra Barnett Zomoroda Abu-Full Naomi Gronich Ronza Najjar-Debbiny Ilana Doweck Gad Rennert Walid Saliba Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
description	ABSTRACT: Background: An excess risk of Bell's palsy has been suggested after mRNA vaccines. We examined the association between the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy. Methods: Using the database of the largest healthcare provider in Israel, we retrieved data from different periods in 2018-2021. Observed cases of Bell's palsy occurring within 21-days after the first vaccine dose and within 30-days after the second vaccine dose were compared to the expected cases, based on the experience of the population in 2019. Standardized incidence ratios (SIRs) and attributable risks (ARs) were computed. Findings: Overall, 132 cases of Bell's palsy were reported in 2,594,990 vaccinees with the first dose, and 152 cases in 2,434,674 vaccinees after the second dose. The age and sex weighted SIRs were 1.36(95% CI, 1.14-1.61) and 1.16(0.99-1.36) after the first and second vaccine dose, respectively. SIRs tended to be higher in older age groups after the first and second vaccine doses. The estimates were more pronounced in older females after the first vaccine dose; SIR=1.71(1.10-2.54) at age 45-64, and 2.51(1.65-3.68) at age ≥65 years. The highest AR was 4.46 per 100,000 vaccinees detected in females aged ≥65 years. In patients with previous history of Bell's palsy, only 4 cases of Bell's palsy were reported in 7,567 vaccinees and 10 cases in 7,045 vaccinees after the first and the second dose, respectively. The age and sex weighted SIRs were 1.15(0.36-2.76) and 2.15(1.09-3.83) after the first and second vaccine dose, respectively. Interpretation: This study suggests that the BNT162b2 mRNA COVID-19 vaccine might be associated with increased risk of Bell's palsy. The small estimated attributable risks suggest that the impact on public health is relatively minor. The benefits of vaccinations explicitly outweigh the possible link to Bell's palsy that has high recovery rate if timely treated with corticosteroids. Funding: No external funding was available for this study.
format	article
author	Rana Shibli Ofra Barnett Zomoroda Abu-Full Naomi Gronich Ronza Najjar-Debbiny Ilana Doweck Gad Rennert Walid Saliba
author_facet	Rana Shibli Ofra Barnett Zomoroda Abu-Full Naomi Gronich Ronza Najjar-Debbiny Ilana Doweck Gad Rennert Walid Saliba
author_sort	Rana Shibli
title	Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
title_short	Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
title_full	Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
title_fullStr	Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
title_full_unstemmed	Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
title_sort	association between vaccination with the bnt162b2 mrna covid-19 vaccine and bell's palsy: a population-based study
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/a4d0dbc2f25d4691a7609a1d56bff071
work_keys_str_mv	AT ranashibli associationbetweenvaccinationwiththebnt162b2mrnacovid19vaccineandbellspalsyapopulationbasedstudy AT ofrabarnett associationbetweenvaccinationwiththebnt162b2mrnacovid19vaccineandbellspalsyapopulationbasedstudy AT zomorodaabufull associationbetweenvaccinationwiththebnt162b2mrnacovid19vaccineandbellspalsyapopulationbasedstudy AT naomigronich associationbetweenvaccinationwiththebnt162b2mrnacovid19vaccineandbellspalsyapopulationbasedstudy AT ronzanajjardebbiny associationbetweenvaccinationwiththebnt162b2mrnacovid19vaccineandbellspalsyapopulationbasedstudy AT ilanadoweck associationbetweenvaccinationwiththebnt162b2mrnacovid19vaccineandbellspalsyapopulationbasedstudy AT gadrennert associationbetweenvaccinationwiththebnt162b2mrnacovid19vaccineandbellspalsyapopulationbasedstudy AT walidsaliba associationbetweenvaccinationwiththebnt162b2mrnacovid19vaccineandbellspalsyapopulationbasedstudy
_version_	1718400666958823424

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study

Ejemplares similares